

Linda S Elting

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6730073/publications.pdf>

Version: 2024-02-01

75
papers

11,084
citations

71102

41
h-index

71685

76
g-index

78
all docs

78
docs citations

78
times ranked

9004
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of head and neck radiotherapy on salivary flow and quality of life: Results of the ORARAD study. <i>Oral Oncology</i> , 2022, 127, 105783.	1.5	12
2	Greater preferences for death in hospital and mechanical ventilation at the end of life among non-whites recently diagnosed with cancer. <i>Supportive Care in Cancer</i> , 2021, 29, 6555-6564.	2.2	4
3	Preferences for More Aggressive End-of-life Pharmacologic Care Among Racial Minorities in a Large Population-Based Cohort of Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 482-491.	1.2	3
4	Evaluation of the Efficacy of a Smoking Cessation Intervention for Cervical Cancer Survivors and Women With High-Grade Cervical Dysplasia: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e34502.	1.0	3
5	Hospice enrollment among cancer patients in Texas covered by Medicare managed care and traditional fee-for-service plans: a statewide population-based study. <i>Supportive Care in Cancer</i> , 2020, 28, 3351-3359.	2.2	10
6	Costs of Oral Complications of Cancer Therapies: Estimates and a Blueprint for Future Study. <i>Journal of the National Cancer Institute Monographs</i> , 2019, 2019, .	2.1	34
7	Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness. <i>Supportive Care in Cancer</i> , 2016, 24, 2695-2706.	2.2	6
8	Variation in Intensity and Costs of Care by Payer and Race for Patients Dying of Cancer in Texas. <i>Medical Care</i> , 2015, 53, 591-598.	2.4	32
9	Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. <i>Supportive Care in Cancer</i> , 2015, 23, 433-439.	2.2	13
10	Geographic Disparities in Mammography Capacity in the South: A Longitudinal Assessment of Supply and Demand. <i>Health Services Research</i> , 2014, 49, 171-185.	2.0	21
11	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2014, 120, 1453-1461.	4.1	838
12	Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 675-680.	2.3	28
13	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. <i>Supportive Care in Cancer</i> , 2013, 21, 3243-3254.	2.2	46
14	Epidemiology and Outcomes of Regimen-Related Toxicities. , 2013, , 3-17.		0
15	A systematic review of trismus induced by cancer therapies in head and neck cancer patients. <i>Supportive Care in Cancer</i> , 2010, 18, 1033-1038.	2.2	172
16	Systematic reviews and guidelines for oral complications of cancer therapies: current challenges and future opportunities. <i>Supportive Care in Cancer</i> , 2010, 18, 977-978.	2.2	21
17	Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature. <i>Supportive Care in Cancer</i> , 2010, 18, 979-984.	2.2	55
18	A systematic review of dental disease in patients undergoing cancer therapy. <i>Supportive Care in Cancer</i> , 2010, 18, 1007-1021.	2.2	209

#	ARTICLE	IF	CITATIONS
19	A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Supportive Care in Cancer, 2010, 18, 1099-1106.	2.2	87
20	A systematic review of oral fungal infections in patients receiving cancer therapy. Supportive Care in Cancer, 2010, 18, 985-992.	2.2	211
21	A systematic review of orofacial pain in patients receiving cancer therapy. Supportive Care in Cancer, 2010, 18, 1023-1031.	2.2	90
22	Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Supportive Care in Cancer, 2010, 18, 1089-1098.	2.2	132
23	A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridae. Supportive Care in Cancer, 2010, 18, 993-1006.	2.2	68
24	A systematic review of dysgeusia induced by cancer therapies. Supportive Care in Cancer, 2010, 18, 1081-1087.	2.2	190
25	Clinical Management of Salivary Gland Hypofunction and Xerostomia in Head-and-Neck Cancer Patients: Successes and Barriers. International Journal of Radiation Oncology Biology Physics, 2010, 78, 983-991.	0.8	278
26	Hospitalizations for infection in cancer patients: impact of an aging population. Supportive Care in Cancer, 2009, 17, 547-554.	2.2	14
27	Mammography Capacity. American Journal of Preventive Medicine, 2009, 37, 102-108.	3.0	56
28	Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study. International Urology and Nephrology, 2008, 40, 893-899.	1.4	28
29	Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer, 2008, 113, 2704-2713.	4.1	310
30	Psychosocial and Economic Impact of Cancer. Dental Clinics of North America, 2008, 52, 231-252.	1.8	8
31	Outcomes and Cost of Outpatient or Inpatient Management of 712 Patients With Febrile Neutropenia. Journal of Clinical Oncology, 2008, 26, 606-611.	1.6	136
32	The Place of Death of Children with Cancer in the Metropolitan Areas of Mexico. Journal of Palliative Medicine, 2008, 11, 973-979.	1.1	12
33	Economic Impact of Palifermin on the Costs of Hospitalization for Autologous Hematopoietic Stem-Cell Transplant: Analysis of Phase 3 Trial Results. Biology of Blood and Marrow Transplantation, 2007, 13, 806-813.	2.0	61
34	Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer, 2007, 109, 820-831.	4.1	692
35	Risk, Outcomes, and Costs of Radiation-Induced Oral Mucositis Among Patients With Head-and-Neck Malignancies. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1110-1120.	0.8	405
36	Factors associated with place of death of cancer patients in the Mexico City Metropolitan area. Supportive Care in Cancer, 2007, 15, 243-249.	2.2	22

#	ARTICLE	IF	CITATIONS
37	Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. <i>Lancet Oncology</i> , The, 2006, 7, 508-514.	10.7	311
38	Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. <i>Supportive Care in Cancer</i> , 2006, 14, 505-515.	2.2	132
39	Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy™Thrombocytopenia (FACT-Th) questionnaire. <i>Supportive Care in Cancer</i> , 2006, 14, 1220-1231.	2.2	19
40	Generalizability of cancer clinical trial results. <i>Cancer</i> , 2006, 106, 2452-2458.	4.1	162
41	Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia. <i>Cancer</i> , 2006, 106, 2489-2494.	4.1	39
42	If at first you don't succeed, don't quit, try again: The Centers For Medicare and Medicaid Services demonstration project on quality of care-2005 and 2006. <i>The Journal of Supportive Oncology</i> , 2006, 4, 147-51.	2.3	1
43	Epidemiology and outcomes of serious influenza-related infections in the cancer population. <i>Cancer</i> , 2005, 104, 618-628.	4.1	162
44	Correlation between annual volume of cystectomy, professional staffing, and outcomes. <i>Cancer</i> , 2005, 104, 975-984.	4.1	130
45	The economic burden of supportive care of cancer patients. <i>Supportive Care in Cancer</i> , 2004, 12, 219-226.	2.2	53
46	Perspectives on cancer therapy-induced mucosal injury. <i>Cancer</i> , 2004, 100, 1995-2025.	4.1	1,214
47	Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. <i>Cancer</i> , 2004, 100, 2026-2046.	4.1	691
48	Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the united states and other countries. <i>American Journal of Medicine</i> , 2004, 116, 28-34.	1.5	18
49	Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis. <i>Seminars in Oncology Nursing</i> , 2004, 20, 3-10.	1.5	66
50	Cost-effectiveness of the bird's nest filter for preventing pulmonary embolism among patients with malignant brain tumors and deep venous thrombosis of the lower extremities. <i>Supportive Care in Cancer</i> , 2003, 11, 795-799.	2.2	28
51	Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. <i>Cancer</i> , 2003, 97, 1541-1550.	4.1	53
52	Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. <i>Cancer</i> , 2003, 97, 3099-3106.	4.1	45
53	The burdens of cancer therapy. <i>Cancer</i> , 2003, 98, 1531-1539.	4.1	520
54	The bleeding risk index. <i>Cancer</i> , 2002, 94, 3252-3262.	4.1	29

#	ARTICLE	IF	CITATIONS
55	Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. <i>Supportive Care in Cancer</i> , 2002, 10, 189-196.	2.2	24
56	Incidence, Cost, and Outcomes of Bleeding and Chemotherapy Dose Modification Among Solid Tumor Patients With Chemotherapy-Induced Thrombocytopenia. <i>Journal of Clinical Oncology</i> , 2001, 19, 1137-1146.	1.6	152
57	Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*. <i>Journal of Clinical Oncology</i> , 2001, 19, 1519-1538.	1.6	546
58	Time to Clinical Response: An Outcome of Antibiotic Therapy of Febrile Neutropenia With Implications for Quality and Cost of Care. <i>Journal of Clinical Oncology</i> , 2000, 18, 3699-3706.	1.6	51
59	The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 3038-3051.	1.6	991
60	Severity of Illness, Outcomes, and Resource Use in Elderly Cancer Patients with Deep Venous Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2000, 6, 175-178.	1.7	4
61	Stratification in clinical trials of febrile neutropenia. <i>Supportive Care in Cancer</i> , 1998, 6, 457-461.	2.2	4
62	Outcomes of Bacteremia in Patients with Cancer and Neutropenia: Observations from Two Decades of Epidemiological and Clinical Trials. <i>Clinical Infectious Diseases</i> , 1997, 25, 247-259.	5.8	365
63	Medical futility and appropriate medical care in patients whose death is thought to be imminent. <i>Supportive Care in Cancer</i> , 1997, 5, 274-280.	2.2	29
64	Controversies in new antibiotic therapy for ambulatory patients. <i>Supportive Care in Cancer</i> , 1997, 5, 358-364.	2.2	8
65	Pharmacoeconomic analyses: Whose perspective counts and costs the most?. <i>American Journal of Health-System Pharmacy</i> , 1994, 51, 1564-1569.	1.0	1
66	Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. <i>Cancer</i> , 1993, 71, 3640-3646.	4.1	273
67	Clostridial bacteremia in cancer patients. A 12-year experience. <i>Cancer</i> , 1991, 67, 1928-1942.	4.1	154
68	β ² -Lactam regimens for the febrile neutropenic patient. <i>Cancer</i> , 1990, 65, 9-16.	4.1	51
69	Nosocomial Infections Due to <i>Xanthomonas maltophilia</i> (<i>Pseudomonas maltophilia</i>) in Patients with Cancer. <i>Clinical Infectious Diseases</i> , 1990, 12, 997-1003.	5.8	185
70	<i>Klebsiella</i> bacteremia. A 10-year review in a cancer institution. <i>Cancer</i> , 1989, 64, 2368-2376.	4.1	40
71	Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. <i>American Journal of Medicine</i> , 1988, 84, 581-589.	1.5	67
72	Imipenem/cilastatin therapy of infections in cancer patients. <i>Cancer</i> , 1987, 60, 255-262.	4.1	33

#	ARTICLE	IF	CITATIONS
73	Aztreonam therapy in neutropenic patients with cancer. American Journal of Medicine, 1986, 81, 243-248.	1.5	90
74	Cefotaxime: single agent therapy for infections in cancer patients with adequate granulocyte counts. Journal of Antimicrobial Chemotherapy, 1985, 15, 91-96.	3.0	9
75	Cefoperazone for the Treatment of Infections in Patients with Cancer. Clinical Infectious Diseases, 1983, 5, S181-S187.	5.8	24